By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
It has been a mixed year for LENZ Therapeutics, Inc. insiders: $655,000 bought by four people and $261,000 sold by one, so more buying than selling overall.
Biggest single buyer: Schimmelpennink Evert B., CEO, with roughly $251,000. That includes C-suite money, which tends to get the most attention.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters. On the institutional side, 144 funds reported holding LENZ at the end of Q2 2026, and more funds bought than sold.
Are insiders buying or selling LENZ stock?
In the last 12 months LENZ Therapeutics, Inc. insiders made open-market purchases worth about $655,000 and sales worth about $261,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in LENZ?
The most recent open-market insider trade in LENZ was filed on 2026-03-30.
How many institutions own LENZ?
144 investment managers reported holding LENZ in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded LENZ?
No congressional trades in LENZ were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).